Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic SuspensionBusiness Wire • 03/25/24
Countdown to Amneal (AMRX) Q4 Earnings: A Look at Estimates Beyond Revenue and EPSZacks Investment Research • 02/27/24
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203Business Wire • 02/27/24
Amneal (AMRX) Shows Fast-paced Momentum But Is Still a Bargain StockZacks Investment Research • 02/21/24
Amneal Announces Complete Response Resubmission for IPX203 New Drug ApplicationGlobeNewsWire • 02/08/24
Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203GlobeNewsWire • 01/25/24
INVESTIGATION ALERT: Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) and Encourages Long-Term Investors to Contact the FirmPRNewsWire • 01/08/24
Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023Business Wire • 01/04/24
Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued CompanySeeking Alpha • 12/10/23
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel CapsulesBusiness Wire • 12/01/23
Amneal (AMRX) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 10/31/23
Amneal Pharmaceuticals (AMRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 10/31/23
Amneal Reports Certain Preliminary Third Quarter 2023 Financial Results and Raises Full Year 2023 Financial GuidanceBusiness Wire • 10/23/23